309 related articles for article (PubMed ID: 12668582)
1. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.
Stalker DJ; Jungbluth GL; Hopkins NK; Batts DH
J Antimicrob Chemother; 2003 May; 51(5):1239-46. PubMed ID: 12668582
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.
Lovering AM; Le Floch R; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Vinsonneau C
J Antimicrob Chemother; 2009 Mar; 63(3):553-9. PubMed ID: 19153078
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic evaluation of linezolid in patients with major thermal injuries].
Le Floch R; Arnould JF; Vinsonneau C; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Lovering AM
Pathol Biol (Paris); 2010 Apr; 58(2):e27-31. PubMed ID: 19854590
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E.
Gordi T; Tan LH; Hong C; Hopkins NJ; Francom SF; Slatter JG; Antal EJ
J Clin Pharmacol; 2003 Oct; 43(10):1161-7. PubMed ID: 14517199
[TBL] [Abstract][Full Text] [Related]
5. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.
Matsumoto K; Takeshita A; Ikawa K; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
Int J Antimicrob Agents; 2010 Aug; 36(2):179-81. PubMed ID: 20392606
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses.
Gee T; Ellis R; Marshall G; Andrews J; Ashby J; Wise R
Antimicrob Agents Chemother; 2001 Jun; 45(6):1843-6. PubMed ID: 11353635
[TBL] [Abstract][Full Text] [Related]
7. Impact of ontogeny on linezolid disposition in neonates and infants.
Kearns GL; Jungbluth GL; Abdel-Rahman SM; Hopkins NK; Welshman IR; Grzebyk RP; Bruss JB; Van Den Anker JN;
Clin Pharmacol Ther; 2003 Nov; 74(5):413-22. PubMed ID: 14586382
[TBL] [Abstract][Full Text] [Related]
8. Linezolid pharmacokinetics in pediatric patients: an overview.
Jungbluth GL; Welshman IR; Hopkins NK
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S153-7. PubMed ID: 14520140
[TBL] [Abstract][Full Text] [Related]
9. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
Gandelman K; Zhu T; Fahmi OA; Glue P; Lian K; Obach RS; Damle B
J Clin Pharmacol; 2011 Feb; 51(2):229-36. PubMed ID: 20371736
[TBL] [Abstract][Full Text] [Related]
10. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis.
Stolle LB; Plock N; Joukhadar C; Arpi M; Emmertsen KJ; Buerger C; Riegels-Nielsen P; Kloft C
Scand J Infect Dis; 2008; 40(1):24-9. PubMed ID: 18097982
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ
Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of linezolid.
French G
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii45-53. PubMed ID: 12730142
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
[TBL] [Abstract][Full Text] [Related]
16. The effect of food on plasma and tissue concentrations of linezolid after multiple doses.
Islinger F; Dehghanyar P; Sauermann R; Bürger C; Kloft C; Müller M; Joukhadar C
Int J Antimicrob Agents; 2006 Feb; 27(2):108-12. PubMed ID: 16388930
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
19. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
20. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.
Saralaya D; Peckham DG; Hulme B; Tobin CM; Denton M; Conway S; Etherington C
J Antimicrob Chemother; 2004 Feb; 53(2):325-8. PubMed ID: 14729733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
